We are pleased to announce the release of Merge eClinicalOS v2016.2.0 on Friday, March 4, 2016.
This release includes updates to the Advanced Expression Editor as well as some enhancements to existing tools.
Here are a few highlights of the upcoming release:
The "iGeneration" expects the latest tech at work
In the past decade, electronic data capture (EDC) technology has proven its ability to fuel quantum leaps in the efficiency, quality and safety of research organizations’ work and, in turn, the quality of therapies and devices brought to patients. EDC software accelerates speed-to-market because researchers can identify and act on opportunities to pivot more quickly when data indicate.
Everything these days is becoming automated, thanks to advances in digital technology. But is more technology always good thing? Here's a brief look at the pros and cons of selected digital technologies – with a special focus on clinical research.
Endpoint Adjudication (EA) is having a bit of a moment.
EA isn't a new concept, really. As long as there have been endpoints in clinical trials, there has been a need to resolve events related to safety and efficacy – and provide standardized endpoint outcomes for those all-important statistical analyses.
What IS changing, however, is the way EA is performed. What used to be a very manual, time-consuming process is being transformed – along with everything else in our day and age – by the internet (and more specifically, the cloud). Electronic endpoint adjudication is gaining in popularity, quickly.
Just last week, Applied Clinical Trials put out a call for input on a new survey designed to evaluate the impact of technology on Endpoint Adjudication processes. In their post, they call Endpoint Adjudication "an emerging field" that is "relatively new, but rapidly gaining traction." They also point out that "the adoption of endpoint adjudication as a business process and operational concept seems to be widely unknown and rarely spoken about in the industry." Interesting. We'll be watching this survey closely!
It goes without saying that we're big believers in the power of technology to gain efficiencies in clinical trials. eCOS has a robust, well-established EA module that's unique in the industry - and we've been offering it for more than 10 years! Our customers consistently tell us they love it. So much so that 90% of the world's top adjudication centers now use our solution.
When you compare paper-based EA processes to digital, the benefits are clear. Check out how much electronic technology can cut timelines in this detailed chart:
eCOS Study Build Program Puts YOU in The Driver's Seat
"Clinical research is all about control – and those who choose careers in this industry want to retain as much control over a project as possible. eClinicalOS plays very nicely with this ideal given that it encourages those working with it (programming, conducting UAT, cleaning, etc.) to become self-sufficient."
-Matt Dickason, Managing Director, Renaissance Associates*
Some time ago, you decided to switch from paper to an eClinical system. But now that you've been with that provider for a while, does your relationship feel a bit...strained?
Merge to become part of IBM’s new Watson Health business unit
Armonk, NY and CHICAGO – 13 Oct, 2015: IBM (NYSE: IBM) today announced that it has completed the acquisition of Merge Healthcare Incorporated, a leading provider of medical image handling and processing, interoperability and clinical systems. Under terms of the $1 billion transaction, Merge shareholders will receive $7.13 per share in cash.
eClinicalOS Welcomes Watson!
The hallways at eClinicalOS headquarters are positively buzzing this week! Why the fuss? Well, we just got some VERY exciting news about our future. (We think you’ll find it to be great news, too!)
Compliance with self-inspection mandate required by August 25th
The China Food and Drug Administration (CFDA) is making a push to ensure the accuracy of clinical trial data and drug quality (as well as proper record-keeping) for its 1,622 currently pending drug registration applications. This includes both imported and local drugs.